EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer

Elena Castro, A Douglas Laird, Niven Mehra, Tanya Dorff, Song Zhao, Inge van Oort, Donatello Gasparro, Fabio Calabrò, Sandro Pignata, Lajos Geczi, Philippe Barthélémy, Deepak Kilari und 8 weitere

European Journal of Cancer · 2026-11 · 248 · 117079

DOI: 10.1016/j.ejca.2026.117079 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Elena Castro und 19 weiteren Autor:innen. Beteiligte Einrichtung: Insituto de Investigación del Hospital Universitario 12 de Octubre (imas12), Madrid, Spain. Electronic address: ecastro.imas12@h12o.es. Hauptthemen laut MEDLINE: Phthalazines, Prostatic Neoplasms, Castration-Resistant, Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesProstatic Neoplasms, Castration-ResistantPoly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmBiomarkers, TumorHumansMaleAgedRetrospective StudiesMiddle AgedGenomicsProgression-Free SurvivalRecombinational DNA RepairBRCA2 ProteinFanconi Anemia Complementation Group N ProteinMutationAged, 80 and over

Stichwörter der Autor:innen

BRCA1BRCA2Homologous recombination repairPALB2PARP inhibitorPARP1 variantTalazoparib reversion mutationmAPMRMAPMRmCRPC

Substanzen

talazoparibPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinFanconi Anemia Complementation Group N ProteinBRCA2 protein, humanBiomarkers, TumorPALB2 protein, human

Autor:innen und Institutionen

  • Insituto de Investigación del Hospital Universitario 12 de Octubre (imas12), Madrid, Spain. Electronic address: ecastro.imas12@h12o.es.
  • Pfizer Inc., South San Francisco, CA, USA.
  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Medical Oncology, Swedish Cancer Institute, Seattle, WA, USA.
  • Department of Urology, University Medical Center Groningen, Groningen, the Netherlands.

Förderung

  • Pfizer Inc

Zitieren

APA

Castro, E., Douglas Laird, A., Mehra, N., Dorff, T., Zhao, S., van Oort, I., Gasparro, D., Calabrò, F., Pignata, S., Geczi, L., Barthélémy, P., Kilari, D., Graf, R. P., Chen, H. C., Healy, C. G., Scagliotti, G. V., Chelliserry, J., Kennedy, D., Fizazi, K., & de Bono, J. S. (2026). Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer, 248, 117079. https://doi.org/10.1016/j.ejca.2026.117079

Vancouver

Castro E, Douglas Laird A, Mehra N, Dorff T, Zhao S, van Oort I, et al. Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer. 2026;248:117079. doi:10.1016/j.ejca.2026.117079

BibTeX
@article{Castro2026,
  author = {Castro, Elena and Douglas Laird, A and Mehra, Niven and Dorff, Tanya and Zhao, Song and van Oort, Inge and Gasparro, Donatello and Calabrò, Fabio and Pignata, Sandro and Geczi, Lajos and Barthélémy, Philippe and Kilari, Deepak and Graf, Ryon P and Chen, Hsiang-Chun and Healy, Cynthia G and Scagliotti, Giorgio V and Chelliserry, Jijumon and Kennedy, Dana and Fizazi, Karim and de Bono, Johann S},
  title = {Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117079},
  doi = {10.1016/j.ejca.2026.117079}
}
Kostenlos starten →